Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: GlobeNewswire
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseasesNomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease and demonstrated development program readinessSTART pilot program is intended to improve development efficiency through enhanced communication with the FDANomlabofusp is expected to be one of three CDER programs and one of six total programs selected by the FDABLA submission continues to be targeted for 2H 2025 BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. Nomlabofusp is a n
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.MarketBeat
- Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia [Yahoo! Finance]Yahoo! Finance
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at Citigroup Inc. from $10.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study [Yahoo! Finance]Yahoo! Finance
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.MarketBeat
LRMR
Earnings
- 3/14/24 - Miss
LRMR
Sec Filings
- 6/10/24 - Form 8-K
- 6/3/24 - Form 4
- 5/31/24 - Form 4
- LRMR's page on the SEC website